Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/155
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFrydenberg, Harryen
dc.date.accessioned2015-05-22T04:06:32Zen
dc.date.available2015-05-22T04:06:32Zen
dc.date.issued2013-08en
dc.identifier.urihttp://hdl.handle.net/11434/155en
dc.description.abstractThe Endobarrier is a 60 cm endoscopically placed endoluminal sleeve, which is made of Teflon and placed into the first part of the duodenum and proceeds 60 cm through to the small bowel bypassing effectively the duodenum and first part of the jejunum (often referred to as a duodenojejunal bypass liner). Studies have been done with implantations up to one year with follow-up results over two years following explanation and these indicate that there is substantial weight loss initially 12 to 24 weeks, which is often maintained for the duration of the implant and this weight loss often extends for further 9 to 12 months following explanation. Good improvement in glycaemic control in type II diabetes is a major feature of the EndoBarrier. Many patients come off both insulin and other medications for type II diabetes and these effects have shown very early in the implantation and once again the beneficial effects in type II diabetes carry on 9 to 12 months after explantation of the device.en
dc.subjectObesityen
dc.subjectObesity, Abdominalen
dc.subjectBariatric Surgeryen
dc.subjectDiabetes Mellitus, Type 2en
dc.subjectWeight Reductionen
dc.subjectWeight Lossen
dc.subjectInsulinen
dc.subjectDuodenumen
dc.subjectJejunumen
dc.subjectConference abstract onlyen
dc.titleEndobarrier duodeno-jejunal bypass liner (endoscopic treatment of type II diabetes and obesity)en
dc.typeConference Paperen
dc.description.affiliatesInternational Federation for the Surgery of Obesity and Metabolic Disordersen
dc.description.affiliatesObesity Surgery Society of Australia and New Zealand OSSANZen
dc.description.affiliatesGastroenterological Society of Australiaen
dc.description.affiliatesAustralasian Society for the Study of Obesityen
dc.type.studyortrialCase Control Studiesen
dc.description.conferencename18th World Congress of the International Federation for the Surgery of Obesity & Metabolic Disorders (IFSO), 28-31 August 2013en
dc.description.conferencelocationIstanbul, Turkey.en
dc.type.contenttypeTexten
Appears in Collections:General Surgery and Gastroenterology

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.